PubRank

Charles A B Boucher

Author PubWeight™ 74.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009 8.37
2 Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009 2.60
3 Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006 2.33
4 Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 2002 2.20
5 Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010 2.13
6 Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010 2.13
7 A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007 1.99
8 Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012 1.95
9 HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009 1.68
10 Transmission networks of HIV-1 among men having sex with men in the Netherlands. AIDS 2010 1.49
11 Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS 2013 1.42
12 [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine]. Ned Tijdschr Geneeskd 2013 1.39
13 Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010 1.34
14 Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med 2006 1.34
15 Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One 2010 1.33
16 HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology 2013 1.30
17 Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 2011 1.28
18 Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2010 1.27
19 The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006 1.27
20 Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009 1.19
21 Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003 1.18
22 The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. Curr Opin Infect Dis 2010 1.14
23 H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog 2012 1.13
24 Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog 2011 1.09
25 Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS 2008 1.08
26 Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis 2006 1.07
27 Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients. Scand J Infect Dis 2012 1.07
28 Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis 2009 1.03
29 Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011 1.02
30 Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology 2013 1.01
31 An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs. J Acquir Immune Defic Syndr 2006 0.99
32 HIV-1 can persist in aged memory CD4+ T lymphocytes with minimal signs of evolution after 8.3 years of effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009 0.98
33 Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis 2009 0.98
34 A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol 2011 0.94
35 The potential for multidrug-resistant influenza. Curr Opin Infect Dis 2011 0.93
36 Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther 2011 0.92
37 Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study. AIDS 2014 0.91
38 Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study. PLoS One 2013 0.88
39 Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Antivir Ther 2012 0.88
40 Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase. Retrovirology 2008 0.85
41 Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach. J Acquir Immune Defic Syndr 2014 0.85
42 Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop. Antivir Ther 2008 0.83
43 Estimates of HIV transmitted drug resistance can be inflated due to natural sequence polymorphisms. J Acquir Immune Defic Syndr 2011 0.83
44 Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. Retrovirology 2012 0.82
45 Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients. J Infect Dis 2002 0.82
46 Therapy failure resulting from superinfection by a drug-resistant HIV variant. Antivir Ther 2012 0.81
47 Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase. Virology 2007 0.81
48 HIV protease resistance and viral fitness. Curr Opin HIV AIDS 2007 0.81
49 Low cost HIV-1 quantitative RT-PCR assay in resource-limited settings: improvement and implementation. J Virol Methods 2012 0.81
50 A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity. PLoS One 2013 0.80
51 Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity. Antiviral Res 2007 0.79
52 Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008. Open Virol J 2011 0.78
53 Case report: oseltamivir-induced resistant pandemic influenza A (H1N1) virus infection in a patient with AIDS and Pneumocystis jirovecii pneumonia. J Med Virol 2013 0.78
54 Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Med 2015 0.78
55 Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations. Antivir Ther 2008 0.78
56 [Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient]. Ned Tijdschr Geneeskd 2010 0.77
57 Ongoing HIV replication in cerebrospinal fluid under successful monotherapy. Antivir Ther 2013 0.77
58 Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein. J Virol 2007 0.77
59 Virological failure and drug resistance during first line anti-retroviral treatment in Indonesia. J Med Virol 2013 0.76
60 HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and curative strategies. Antivir Ther 2011 0.76
61 Unite forces to validate biomarkers in the quest for lasting HIV remission. AIDS 2016 0.75
62 Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop. Antivir Ther 2009 0.75